Reviewer’s report

Title: Adverse Infusion Reactions to Rituximab in Systemic Lupus Erythematosus: A Retrospective analysis

Version: 0 Date: 25 Nov 2018

Reviewer: Shereen Oon

Reviewer's report:

An interesting study, that will make a worthwhile contribution to the existing understanding regarding rituximab infusions in autoimmune disease.

Minor points
Table 4 - in text, two of three patients who were retreated had further reaction - according to table, only one is listed, can the other patient data be added to the table?

Table 5 - could you include further detail on how proposed mechanism was determined as unlikely/likely due to cytokine release vs likely Ig mediated, given that clinically they can be difficult to distinguish?

There are a few minor editing errors throughout e.g. page 5, line 5; page 7, line 45.

Consider embedding reference to tables with the corresponding sentence e.g. 'We then went on to classify the reaction by proposed mechanism…(Table 5)'

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.
Yes

**Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?**
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

**Quality of written English**
Please indicate the quality of language in the manuscript:

Acceptable

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests in relation to this manuscript.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my
report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal